Open Access Open Access  Restricted Access Subscription Access

Indications, Mechanism of Action, Administration, Recommended Dosage, Pregnancy Considerations, Adverse Effects and Toxicity of Niacin

Dr. G. Sri Manjula, Ramanjaneyulu D. V., Muralinath E., Guruprasad M., Sravani Pragna K., Manjari P., Sony Sharlet E., T. Nikhil, V. Yaswanth Sai, D. Kusuma Latha, R. Faith Rani, P. Megha Varna

Abstract


The complete range of niacin's applications is still unknown. This activity helps in promoting knowledge of the benefits niacin has to offer, not only for treatment but also in reducing the incidence of certain diseases. This activity explains about the pharmacokinetic, administration, indications, contraindications, adverse effects, monitoring, toxicity, and, most importantly, how to promote interprofessional team outcomes by monitoring the use of this medication in an effective manner.


Full Text:

PDF

References


Kei, A., Liberopoulos, E. N., & Elisaf, M. S. (2011). What restricts the clinical use of nicotinic acid? Current Vascular Pharmacology, 9(4), 521–530.

Fricker, R. A., Green, E. L., Jenkins, S. I., & Griffin, S. M. (2018). The influence of nicotinamide on health and disease in the central nervous system. International Journal of Tryptophan Research, 11, 1178646918776658.

Goldberg, R. B., & Jacobson, T. A. (2008). Effects of niacin on glucose control in patients with dyslipidemia. Mayo Clinic Proceedings, 83(4), 470–478.

Wierzbicki, A. S. (2011). Niacin: The only vitamin that reduces cardiovascular events. International Journal of Clinical Practice, 65(4), 379–385.

Florentin, M., Liberopoulos, E. N., Kei, A., Mikhailidis, D. P., & Elisaf, M. S. (2011). Pleiotropic effects of nicotinic acid: Beyond high-density lipoprotein cholesterol elevation. Current Vascular Pharmacology, 9(4), 385–400.

Hoffer, A. (1959). Treatment of arthritis by nicotinic acid and nicotinamide. Canadian Medical Association Journal, 81(4), 235–238.

Xu, X. J., & Jiang, G. S. (2015). Niacin-respondent subset of schizophrenia: A therapeutic review. European Review for Medical and Pharmacological Sciences, 19(6), 988–997.

Taketani, Y., Masuda, M., Yamanaka-Okumura, H., Tatsumi, S., Segawa, H., Miyamoto, K., Takeda, E., & Yamamoto, H. (2015). Niacin and chronic kidney disease. Journal of Nutritional Science and Vitaminology (Tokyo), 61(Suppl), S173–S175.

Park, S. M., Li, T., Wu, S., Li, W. Q., Weinstock, M., Qureshi, A. A., & Cho, E. (2017). Niacin intake and risk of skin cancer in U.S. women and men. International Journal of Cancer, 140(9), 2023–2031.

Motawi, T. K., Darwish, H. A., Hamed, M. A., El-Rigal, N. S., & Aboul Naser, A. F. (2017). Coenzyme Q10 and niacin mitigate streptozotocin-induced diabetic encephalopathy in a rat model. Metabolic Brain Disease, 32(5), 1519–1527.

Gille, A., Bodor, E. T., Ahmed, K., & Offermanns, S. (2008). Nicotinic acid: Pharmacological effects and mechanisms of action. Annual Review of Pharmacology and Toxicology, 48, 79–106.

Montecucco, F., Quercioli, A., Dallegri, F., Viviani, G. L., & Mach, F. (2010). New evidence for nicotinic acid treatment to reduce atherosclerosis. Expert Review of Cardiovascular Therapy, 8(10), 1457–1467.

Meyer-Ficca, M., & Kirkland, J. B. (2016). Niacin. Advances in Nutrition, 7(3), 556–558.

Imai, S., & Guarente, L. (2014). NAD+ and sirtuins in aging and disease. Trends in Cell Biology, 24(8), 464–471.

Li, J., Qu, J., Shi, Y., Perfetto, M., Ping, Z., Christian, L., Niu, H., Mei, S., Zhang, Q., Yang, X., & Wei, S. (2017). Nicotinic acid inhibits glioma invasion by facilitating Snail1 degradation. Scientific Reports, 7, 43173.


Refbacks

  • There are currently no refbacks.